Ƶ

ADHD and Car Crashes; New Guidance on Stimulant Use Disorder Tx; KarXT Heads to FDA

— News and commentary from the psychiatry world

Ƶ MedicalToday
Illustration of a brain shaped maze.

Older adults with attention deficit-hyperactivity disorder (ADHD) had a significantly . (JAMA Network Open)

Meanwhile, the in kids 4 years and up held steady -- between 10.08% to 10.47% -- from 2017 to 2022, according to nationally representative data. (JAMA Network Open)

The FDA released new draft guidance to help sponsors develop .

From January 2019 to August 2022, rose by 22% in the U.S. (JAMA Network Open)

People on for schizophrenia saw no impact on social functioning after 2 years of supported dose reduction compared with those who stayed on therapy. (The Lancet Psychiatry)

More than half of and a third take medication for it, according to a survey from Harmony Healthcare IT.

Seven California counties started a to help connect people with untreated schizophrenia with housing and medical care -- sometimes even without their consent. (AP)

Karuna Therapeutics submitted a new drug application to the FDA for its investigational schizophrenia treatment , with supporting data from the EMERGENT clinical program.

Researchers developed an individual-level prediction tool for by week 3 of treatment. (JAMA Psychiatry)

A former director of an Ohio memory-loss clinic and her physician husband were for falsely diagnosing patients with Alzheimer's disease. (AP)

Mood changes weren't uncommon during the monthly "pill pause" for , especially for women with baseline depression. (JAMA Network Open)

may have a genetic predisposition to smoking but a reduced genetic risk of obesity. (American Journal of Psychiatry)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.